MASS - 908 Devices Inc. Stock Price, Fair Value and News

5.62USD+0.06 (+1.08%)Market Closed

Market Summary

USD5.62+0.06

Market Closed

1.08%

MASS Stock Price

View Fullscreen

MASS RSI Chart

MASS Valuation

Market Cap

185.0M

Price/Earnings (Trailing)

-5.08

Price/Sales (Trailing)

3.68

EV/EBITDA

-1.88

Price/Free Cashflow

-6.82

MASS Price/Sales (Trailing)

MASS Profitability

Operating Margin

50.41%

EBT Margin

-72.89%

Return on Equity

-21.99%

Return on Assets

-17.93%

Free Cashflow Yield

-14.65%

MASS Fundamentals

MASS Revenue

Revenue (TTM)

50.2M

Rev. Growth (Yr)

23.26%

Rev. Growth (Qtr)

0.38%

MASS Earnings

Earnings (TTM)

-36.4M

Earnings Growth (Yr)

24.13%

Earnings Growth (Qtr)

-4.73%

Breaking Down MASS Revenue

Last 7 days

-4.0%

Last 30 days

-17.0%

Last 90 days

-28.3%

Trailing 12 Months

-26.7%

How does MASS drawdown profile look like?

MASS Financial Health

Current Ratio

7.71

Debt/Equity

0.09

Debt/Cashflow

-1.67

MASS Investor Care

Shares Dilution (1Y)

2.11%

Diluted EPS (TTM)

-1.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	48.0M	49.0M	47.5M	50.2M
2022	45.0M	47.8M	51.0M	46.9M
2021	28.4M	25.6M	32.1M	42.2M
2020	0	0	0	26.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of 908 Devices Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 16, 2024	knopp kevin j.	acquired	82,250	1.75	47,000	president and ceo
Apr 01, 2024	brown christopher d.	acquired	6,300	1.75	3,600	chief product officer
Mar 26, 2024	griffith joseph h. iv	acquired	13,330	1.58	8,437	chief financial officer
Mar 04, 2024	hunt anthony	acquired	-	-	2,057	-
Feb 22, 2024	eloi fenel m	acquired	-	-	508	-
Feb 22, 2024	george jeffrey p.	acquired	-	-	508	-
Feb 02, 2024	griffith joseph h. iv	sold	-68,873	7.0923	-9,711	chief financial officer
Feb 01, 2024	turner michael s.	acquired	-	-	14,337	chief legal & admin officer
Feb 01, 2024	griffith joseph h. iv	sold	-39,892	7.00108	-5,698	chief financial officer
Feb 01, 2024	brown christopher d.	acquired	-	-	12,446	chief product officer

Which funds bought or sold MASS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-56.48	-14,000	6,000	-%
Apr 23, 2024	Values First Advisors, Inc.	reduced	-26.04	-95,834	94,940	0.06%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	54,675	134,528	-%
Apr 19, 2024	Sumitomo Mitsui Trust Holdings, Inc.	reduced	-3.39	-2,285,100	4,245,320	-%
Apr 18, 2024	ARK Investment Management LLC	reduced	-6.85	-18,199,100	30,569,500	0.21%
Apr 03, 2024	Versant Capital Management, Inc	sold off	-100	-516	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-66.67	-53.00	67.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.93	8,174,220	19,571,400	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	132	472,331	634,582	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	49,420	122,320	-%

Are Funds Buying or Selling MASS?

Are funds buying MASS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MASS

No. of Funds

Unveiling 908 Devices Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ameriprise financial inc	5.84%	1,889,627	SC 13G
Feb 14, 2024	eventide asset management, llc	4.42%	1,430,995	SC 13G/A
Feb 14, 2024	granahan investment management, llc	6.30%	2,038,658	SC 13G
Feb 13, 2024	vanguard group inc	5.39%	1,744,330	SC 13G
Feb 09, 2024	arch venture fund vii, l.p.	17.7%	5,725,045	SC 13G/A
Jan 31, 2024	blackrock inc.	5.5%	1,786,753	SC 13G/A
Jan 29, 2024	ark investment management llc	13.42%	4,346,579	SC 13G/A
Nov 13, 2023	alger associates inc	3.8%	1,227,494	SC 13G/A
Feb 14, 2023	alger associates inc	8.8%	2,805,216	SC 13G/A
Feb 14, 2023	eventide asset management, llc	7.0%	2,230,665	SC 13G

Recent SEC filings of 908 Devices Inc.

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 08, 2024	10-K	Annual Report
Mar 08, 2024	S-8	Employee Benefits Plan
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to 908 Devices Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.69%	-2.54%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-4.86%	-10.59%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-2.36%	-14.10%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.62	0.76	-2.44%	-22.68%
ATR	9.2B	3.5B	-1.02%	16.40%	32.49	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.63%	-38.25%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-560.04	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.12	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	384.6M	166.7M	1.30%	-3.37%	-4.65	2.31	6.67%	-456.34%
ANGO	235.1M	324.0M	12.50%	-31.24%	-1.22	0.73	-3.19%	-337.41%
APYX	45.7M	52.3M	5.60%	-56.15%	-2.44	0.87	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.33	1.07	5.77%	8.23%

908 Devices Inc. News

Latest updates

908 Devices Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	0.4%	14,351,000	14,297,000	12,094,000	9,487,000	11,643,000	15,797,000	11,106,000	8,306,000	15,841,000	12,545,000	8,277,000	5,543,000	5,717,000	6,048,000	11,128,000	4,001,000
Cost Of Revenue	10.1%	7,076,000	6,428,000	6,300,000	5,103,000	5,721,000	6,459,000	4,472,000	4,177,000	6,707,000	5,733,000	3,898,000	2,635,000	3,138,000	2,212,000	4,718,000	1,903,000
Gross Profit	-7.5%	7,275,000	7,869,000	5,794,000	4,384,000	5,922,000	9,338,000	6,634,000	4,129,000	9,134,000	6,812,000	4,379,000	2,908,000	2,579,000	3,836,000	6,410,000	2,098,000
Operating Expenses	0.2%	16,988,000	16,958,000	16,733,000	17,401,000	16,260,000	16,492,000	15,003,000	13,650,000	12,662,000	12,088,000	11,834,000	8,718,000	6,465,000	5,129,000	4,282,000	4,862,000
S&GA Expenses	1.1%	11,544,000	11,421,000	11,208,000	12,003,000	11,598,000	11,826,000	10,710,000	9,745,000	8,917,000	8,786,000	8,779,000	5,753,000	4,183,000	3,178,000	2,436,000	2,706,000
R&D Expenses	-1.7%	5,444,000	5,537,000	5,525,000	5,398,000	4,662,000	4,666,000	4,293,000	3,905,000	3,745,000	3,302,000	3,055,000	2,965,000	2,282,000	1,951,000	1,846,000	2,156,000
EBITDA Margin	-Infinity%	-0.68	-	-0.63	-0.64	-0.68	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	100.0%	-	-350,000	-	551,000	61,000	33,000	15,000	20,000	40,000	31,000	39,000	376,000	244,000	245,000	246,000	241,000
Income Taxes	110.3%	9,000	-87,000	-71,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-3.5%	-7,431,000	-7,180,000	-9,417,000	-	-	-6,259,000	-8,099,000	-	-	-	-	-	-	-	-	-
EBT Margin	-Infinity%	-0.73	-	-0.68	-0.70	-0.72	-	-	-	-	-	-	-	-	-	-	-
Net Income	-4.7%	-7,428,500	-7,093,000	-9,346,000	-12,532,000	-9,790,500	-6,259,000	-8,099,000	-9,415,000	-3,465,000	-5,185,000	-7,424,000	-6,095,000	-10,226,000	-1,722,000	2,095,000	-2,966,000
Net Income Margin	11.2%	-0.72	-0.82	-0.77	-0.76	-0.72	-0.53	-0.55	-0.57	-0.53	-0.90	-1.00	-0.56	-0.48	-	-	-
Free Cashflow	52.9%	-2,263,000	-4,807,000	-8,202,000	-11,832,000	-5,728,000	-5,682,000	-10,482,000	-1,083,000	-9,274,000	-2,982,000	-7,921,000	-9,642,000	2,332,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-2.6%	203	208	211	218	243	249	247	251	261	166	166	172	179
Current Assets	-3.4%	174	180	181	188	216	224	239	243	253	157	157	163	171
Cash Equivalents	2.4%	121	118	133	161	188	194	213	223	224	139	141	149	159
Inventory	-6.2%	15.00	16.00	14.00	13.00	13.00	12.00	11.00	10.00	8.00	8.00	8.00	7.00	5.00
Net PPE	17.1%	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00
Goodwill	4.4%	10.00	10.00	10.00	10.00	10.00	9.00	-	-	-	-	-	-	-
Liabilities	-2.7%	37.00	39.00	36.00	38.00	52.00	53.00	46.00	44.00	46.00	44.00	40.00	38.00	40.00
Current Liabilities	1.0%	23.00	22.00	20.00	19.00	19.00	19.00	15.00	14.00	15.00	13.00	11.00	9.00	11.00
Long Term Debt	-	-	-	-	-	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	14.00
LT Debt, Non Current	-	-	-	-	-	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	14.00
Shareholder's Equity	-2.6%	165	170	174	181	191	197	201	207	215	123	127	133	139
Retained Earnings	-4.6%	-170	-163	-156	-146	-134	-124	-118	-110	-100	-97.17	-92.00	-84.60	-78.47
Additional Paid-In Capital	0.8%	335	332	329	326	324	321	319	317	315	220	219	218	217
Shares Outstanding	0.5%	33.00	32.00	32.00	32.00	32.00	31.00	31.00	31.00	31.00	28.00	27.00	27.00	-
Float	-	-	-	166	-	-	-	474	-	-	-	675	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	58.0%	-1,930	-4,600	-7,882	-10,647	-5,116	-4,938	-10,410	-466	-9,220	-2,924	-7,305	-9,633	2,332	8,197	-3,230	-3,168
Share Based Compensation	-13.5%	2,339	2,704	2,578	2,166	2,004	2,020	1,894	1,289	873	811	481	339	307	83.00	69.00	66.00
Cashflow From Investing	146.8%	4,636	-9,915	-19,936	-1,185	-612	-14,506	-72.00	-617	-54.00	-58.00	-616	-9.00	-	175	-93.00	-91.00
Cashflow From Financing	138.3%	95.00	-248	-401	-15,381	411	171	467	130	94,532	483	276	-566	137,183	5.00	1.00	3.00

MASS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 50,229	$ 46,852
Cost of revenue	24,907	20,829
Gross profit	25,322	26,023
Operating expenses:
Research and development	21,904	17,526
Selling, general and administrative	46,176	43,879
Total operating expenses	68,080	61,405
Loss from operations	(42,758)	(35,382)
Other income, net:
Interest income	6,480	2,031
Interest expense	(201)	(129)
Other expense, net	(131)	(83)
Total other income, net	6,148	1,819
Loss from operations before income taxes	(36,610)	(33,563)
Benefit for income taxes	211	0
Net loss	$ (36,399)	$ (33,563)
Net loss per share, basic	$ (1.13)	$ (1.07)
Net loss per share, diluted	$ (1.13)	$ (1.07)
Weighted average common shares outstanding, basic	32,239,394	31,492,531
Weighted average common shares outstanding, diluted	32,239,394	31,492,531
Product revenue
Revenue	$ 40,214	$ 37,499
Cost of revenue	18,428	16,010
Service revenue
Revenue	9,645	6,976
Cost of revenue	6,380	4,420
Contract revenue
Revenue	370	2,377
Cost of revenue	$ 99	$ 399

MASS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 121,041	$ 188,422
Marketable securities	24,641
Accounts receivable, net of allowance for credit losses of $395 and $25 at December 31, 2023 and December 31, 2022	8,989	10,033
Inventory	14,938	12,513
Prepaid expenses and other current assets	4,181	4,658
Total current assets	173,790	215,626
Operating lease, right-of-use assets	6,233	3,956
Property and equipment, net	3,342	3,083
Goodwill	10,367	10,050
Intangible assets, net	7,860	8,488
Other long-term assets	1,389	1,384
Total assets	202,981	242,587
Current liabilities:
Accounts payable	1,191	1,397
Accrued expenses	8,713	8,847
Deferred revenue	10,629	7,514
Operating lease liabilities	2,016	1,468
Total current liabilities	22,549	19,226
Long-term debt		15,000
Operating lease liabilities, net of current portion	3,929	3,040
Deferred revenue, net of current portion	8,571	11,496
Deferred income taxes	2,441	2,671
Other long-term liabilities		555
Total liabilities	37,490	51,988
Commitments and contingencies (Note 15)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding at December 31, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 32,519,023 shares and 31,859,847 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	33	32
Additional paid-in capital	334,692	323,969
Accumulated other comprehensive income	1,365	798
Accumulated deficit	(170,599)	(134,200)
Total stockholders' equity	165,491	190,599
Total liabilities and stockholders' equity	$ 202,981	$ 242,587

About 908 Devices Inc.

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

CEO	Dr. Kevin J. Knopp Ph.D.
WEBSITE	908devices.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	227

908 Devices Inc. Frequently Asked Questions

What is the ticker symbol for 908 Devices Inc.? What does MASS stand for in stocks?

MASS is the stock ticker symbol of 908 Devices Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 908 Devices Inc. (MASS)?

As of Tue Apr 23 2024, market cap of 908 Devices Inc. is 182.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MASS stock?

You can check MASS's fair value in chart for subscribers.

What is the fair value of MASS stock?

You can check MASS's fair value in chart for subscribers. The fair value of 908 Devices Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 908 Devices Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MASS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 908 Devices Inc. a good stock to buy?

The fair value guage provides a quick view whether MASS is over valued or under valued. Whether 908 Devices Inc. is cheap or expensive depends on the assumptions which impact 908 Devices Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MASS.

What is 908 Devices Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, MASS's PE ratio (Price to Earnings) is -5.03 and Price to Sales (PS) ratio is 3.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MASS PE ratio will change depending on the future growth rate expectations of investors.